Posted: March 9, 2018
In late February, Michigan enacted a biosimilar substitution law that promises to improve uptake of biosimilars, while maintaining appropriate patient protections by requiring notification of substitutions to prescribers.
In signing HB 4472, Michigan’s Governor made it the 38th state to enact such legislation. We applaud the legislature and the Governor for enacting regulations that properly balance market access issues with patient safety issues.
For more information on all types of patient advocacy, continue to track the CSRO website and also visit our Facebook page
